Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
OMJJARA ▶︎ (momelotinib) Events
GSK has partnered with myelofibrosis experts to offer webinars and events on the subjects that matter to you
Learn More about Omjjara from Expert Healthcare Professionals in your Region
We run expert-led regional and local events throughout the year, exploring the clinical data of Omjjara and discussing management of real world case studies in clinical practice. Reach out to your local GSK representative to find out more about upcoming events in your area.
INDICATION
Omjjara ▼ (momelotinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.1
▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com
Reference:
- OMJJARA UK SmPC https://www.medicines.org.uk/emc/product/15492/smpc
May 2026 | PM-GB-MML-WCNT-260001 (V1.0)
